UNSPSC 51111758: Panitumumab

This classification denotes a monoclonal antibody with the molecular formula C6398H9878N1694O2016S48, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6A901E312A, more generally known as panitumumab. European Medicines Agency schedules panitumumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25390. The term PANITUMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53.

Most nations schedule Panitumumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, PANITUMUMAB remains the US FDA Preferred Term for this commodity.. Panitumumab bears US NLM identifiers UMLS ID C0879427 and NCI Concept Code C1857.

UNSPSC 51111758 Panitumumab (Commodity) names a specific monoclonal-antibody cancer therapeutic, but recent state and local procurement activity under this code shows little actual buying of panitumumab itself. Instead, the opportunities tagged to this code reflect broader pharmaceutical supply contracting — warehouse piggyback orders and drug-supply acquisitions through cooperative purchasing vehicles and direct competitive bids. State and local health departments, counties, and community health agencies use this code space to procure pharmaceuticals through established master agreements or volume contracts, often bundling multiple drug products under a single solicitation or award rather than buying panitumumab as a discrete line item.

Recent activity spans Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for a piggyback pharmaceutical warehouse order covering Doxycycline Hyclate and Ciprofloxacin Hydrochloride under an Invitation for Bid process, with an initial 12-month term and renewal options through year 3. Seminole County, Florida posted an IFB in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for quarterly delivery to its Community Health Building, with a two-year initial term and one-year renewal option; that procurement included FEMA funding and required E-Verify compliance and standard insurance coverage. The code shows sparse recent activity and significant disconnect between its nominal scope (panitumumab, a specific injectable oncology drug) and the actual procurement patterns (broad pharmaceutical supply and public-health commodity orders). Firms pursuing pharmaceutical supply contracts should track cooperative purchasing vehicles and county health department RFQs rather than expect direct solicitations for this specific therapeutic.